Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
FATE Fate Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: FATE
Price (delayed)
$1.07
Market cap
$122.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
$150.84M
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture
Highlights
FATE's EPS is up by 22% year-on-year and by 9% since the previous quarter
The company's quick ratio rose by 18% QoQ and by 2% YoY
The gross profit has surged by 106% year-on-year but it has declined by 2.2% since the previous quarter
FATE's revenue has surged by 106% year-on-year but it is down by 2.2% since the previous quarter
The company's equity fell by 32% YoY and by 10% QoQ
Key stats
What are the main financial stats of FATE
Market
Valuations
Earnings
Shares outstanding
114.63M
Market cap
$122.66M
Enterprise value
$150.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.43
Price to sales (P/S)
9.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.31
Revenue
$13.34M
Gross profit
$13.34M
Operating income
-$200.49M
Net income
-$175.88M
EBIT
-$175.88M
EBITDA
-$158.41M
Free cash flow
-$125.17M
Per share
Balance sheet
Liquidity
EPS
-$1.5
EPS diluted
-$1.5
Free cash flow per share
-$1.06
Book value per share
$2.52
Revenue per share
$0.11
TBVPS
$3.37
Total assets
$398.67M
Total liabilities
$110.26M
Debt
$83.33M
Equity
$288.41M
Working capital
$220.06M
Debt to equity
0.29
Current ratio
8.81
Quick ratio
8.99
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
-1,187.9%
Gross margin
100%
Net margin
-1,318.9%
Operating margin
-1,503.5%
Return on assets
-37.8%
Return on equity
-51.5%
Return on invested capital
-37.2%
Return on capital employed
-47.5%
Return on sales
-1,318.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FATE stock price
How has the Fate Therapeutics stock price performed over time
Intraday
5.94%
1 week
2.88%
1 month
1.9%
1 year
-74.15%
YTD
-35.15%
QTD
35.43%
Financial performance
How have Fate Therapeutics's revenue and profit performed over time
Revenue
$13.34M
Gross profit
$13.34M
Operating income
-$200.49M
Net income
-$175.88M
Gross margin
100%
Net margin
-1,318.9%
The gross profit has surged by 106% year-on-year but it has declined by 2.2% since the previous quarter
FATE's revenue has surged by 106% year-on-year but it is down by 2.2% since the previous quarter
The net margin has surged by 55% year-on-year and by 3.5% since the previous quarter
The operating margin has soared by 54% YoY and by 2.5% from the previous quarter
Price vs fundamentals
How does FATE's price correlate with its fundamentals
Growth
What is Fate Therapeutics's growth rate over time
Valuation
What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
0.43
P/S
9.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.31
FATE's EPS is up by 22% year-on-year and by 9% since the previous quarter
FATE's price to book (P/B) is 91% lower than its 5-year quarterly average of 4.8 and 39% lower than its last 4 quarters average of 0.7
The company's equity fell by 32% YoY and by 10% QoQ
FATE's revenue has surged by 106% year-on-year but it is down by 2.2% since the previous quarter
The stock's price to sales (P/S) is 88% less than its 5-year quarterly average of 77.4 and 54% less than its last 4 quarters average of 20.7
Efficiency
How efficient is Fate Therapeutics business performance
FATE's return on sales has surged by 55% year-on-year and by 3.5% since the previous quarter
The ROE has contracted by 11% YoY and by 4% from the previous quarter
Fate Therapeutics's return on assets has decreased by 10% YoY and by 3.3% QoQ
The ROIC has contracted by 5% YoY
Dividends
What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FATE.
Financial health
How did Fate Therapeutics financials performed over time
FATE's total assets is down by 30% year-on-year and by 10% since the previous quarter
The total liabilities has contracted by 23% YoY and by 10% from the previous quarter
The debt is 71% smaller than the equity
The company's equity fell by 32% YoY and by 10% QoQ
The company's debt to equity rose by 21% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.